CLX

Business Profile & Competitive Position

The Clorox Company is a Consumer Defensive name in the Household & Personal Products industry. It is a multinational manufacturer and marketer of consumer and professional products, reporting fiscal 2026 net sales of $6.7 billion and employing roughly 9,200 people across approximately 25 countries while selling into about 95 markets. Its consumer-facing portfolio includes Clorox, Pine-Sol, Glad, Fresh Step, Kingsford, Hidden Valley, Brita, and Burt’s Bees, while its professional arm sells under the Purell, CloroxPro, and Clorox Healthcare brands. In April 2026 the company completed the acquisition of GOJO Industries, expanding its health and hygiene business and deepening its business-to-business presence.

Competitive positioning here rests largely on brand equity and shelf presence rather than technological differentiation. The 8.7% net margin is healthy for a packaged-goods staple but not spectacular, consistent with an industry where pricing power must offset commodity and promotional pressure. The more striking figure is the -1,893.5% return on equity. Mathematically, a negative ROE of that magnitude tells you net income is being divided by a negative shareholders’ equity base, which typically happens when long-running buybacks or accumulated losses have pushed book value below zero. That does not imply the operating business is unprofitable, but it does mean ROE cannot be interpreted as a normal “return on book capital” metric. Taken together, the brand portfolio, the $6.7 billion sales base, the low 0.54 beta, and the modest but positive net margin paint a picture of a stable, cash-generating consumer franchise whose balance sheet has been heavily reshaped rather than a high-growth compounder.

Financial Posture

Clorox currently carries a $10.9 billion market capitalization and trades at a P/E of 18.6. That valuation prices the stock as a defensive cash-flow business, but it also embeds an expectation of profit recovery because the company’s fiscal 2026 diluted EPS fell 26% year over year. The 8.7% net margin confirms profitability at the operating line, while the beta of 0.54 signals materially lower systematic volatility than the broad market.

At the latest price of $89.73, the stock is roughly 8.6% below its 50-day exponential moving average of $98.14 and its RSI sits at 30.1, right at the conventional oversold threshold. These technical readings suggest short-term sentiment has weakened, but they do not by themselves indicate a directional edge. The combination of a mid-teens P/E, a low beta, and a negative ROE makes the financial posture unusual: earnings-based valuation looks reasonable by consumer-staples standards, while the equity base is so small or negative that traditional book-value metrics are effectively meaningless.

Strategic Priorities & Outlook

Clorox’s most recent 10-K frames its near-term agenda around the IGNITE strategy and four explicit choices: fueling long-term profitable growth, innovating consumer experiences, reimagining how the company and its people work, and continuously evolving the product portfolio. Operationally, management says it is working to complete and optimize a new enterprise resource planning (ERP) system as part of a broader digital transformation intended to generate long-term efficiencies across supply chain, digital commerce, innovation, and brand building.

The company also says it will invest in strong brands, strategic digital capabilities, and a streamlined operating model to build what it calls a more resilient company capable of delivering consistent, profitable growth. A major focus is advancing health and hygiene expansion and portfolio optimization, which includes integrating the GOJO acquisition and growing in professional and institutional markets.

Near-term results have been pressured. Fiscal 2026 brought declines in organic sales and earnings, with diluted EPS down 26%, partly because macroeconomic headwinds and ERP-transition timing had pulled some sales into fiscal 2025. Customer concentration is another structural consideration: Walmart accounted for 26% of consolidated FY2026 net sales, and the five largest customers represented roughly half. Separately, the Glad bags and wraps venture with P&G expired on January 31, 2026, requiring Clorox to purchase P&G’s 20% interest; Glad retained core intellectual-property licenses on a royalty-free basis.

Macro & Geopolitical Exposure

As a Household & Personal Products manufacturer, Clorox sits in a sector whose exposures are more operational than cyclical. The business is defensive in demand terms, but margins are still sensitive to commodity inputs such as resins, wood pulp, chemicals, and packaging materials, along with freight and transportation costs. Currency translation matters for a company operating in roughly 25 countries and selling into about 95 markets, while tariffs on imported raw materials or finished goods could affect both cost structure and supply-chain routing.

Regulatory exposure is also inherent in this industry, particularly for cleaning and disinfecting products that fall under EPA and similar oversight regimes abroad. Retailer concentration amplifies macro risk in another way: with Walmart alone representing 26% of FY2026 net sales and the top five customers near 50%, pricing negotiations and inventory adjustments at a handful of retailers can have an outsized impact on quarterly results. Private-label competition and consumer trade-down behavior during periods of stretched household budgets add further pressure, even when absolute demand for cleaning and personal-care staples remains stable.

Recent Developments

Recent headlines capture the mix of institutional positioning and investor scrutiny surrounding the stock. On September 14, 2026, defenseworld.net reported that NewEdge Advisors LLC had acquired shares of CLX. On September 9, 2026, Seeking Alpha published the transcript of Clorox’s presentation at the Barclays 19th Annual Global Consumer Staples Conference, giving investors a direct read on management messaging. That same day, 247wallst.com included Clorox in a discussion of passive-income investors buying well-known high-yield stocks near 52-week lows. Earlier, on September 3, 2026, Zacks asked whether cost savings can offset inflation and protect Clorox’s margins, a question that ties directly to the ERP-driven efficiency goals and the 8.7% net margin investors are watching.

Earnings Behavior & Post-Earnings Drift

Clorox has delivered earnings beats in six of the last eight reported quarters, a 75% beat rate, with an average earnings surprise of 9.6%. The average five-day price move in the trading sessions after those reports has been +1.67%, classified as an upward post-earnings drift. Beneath that average, however, the reaction pattern has been volatile and not always aligned with the direction of the surprise.

In the most recent four quarters, Clorox reported $1.66 versus a $1.64 estimate on August 3, 2026, a 1.2% beat that was followed by a +6.52% next-day move and a +9.61% gain over the following five days. On April 30, 2026, it beat by 5.8% with $1.64 against $1.55, yet the stock fell 9.67% the next day and was down 4.49% over the next five sessions. The February 3, 2026 quarter was a 2.8% miss at $1.39 versus $1.43, but the stock rose 2.43% the next day and 5.63% over five days. Finally, the November 3, 2025 report showed a 3.9% beat at $0.85 versus $0.818, producing a +1.17% next-day move but a -4.08% five-day drift. Clorox is scheduled to report next on November 3, 2026, after the close, with a consensus EPS estimate of $1.11.

For a deeper dive into how sell-side analysts, quant models, and options markets are pricing Clorox ahead of the November 3, 2026 report, take a look at the full institutional verdict on the ticker page.